Drug Type Bispecific killer cell engager (BiKE) |
Synonyms Anti-CD30/anti-CD16A antibody (Affimed), TandAb AFM13 + [1] |
Target |
Action modulators |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationRegenerative Medicine Advanced Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | Turkey | 13 Nov 2019 | |
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | France | 13 Nov 2019 | |
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | Italy | 13 Nov 2019 | |
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 2 | Poland | 13 Nov 2019 | |
CD-30 positive Lymphoma | Phase 2 | United States | 17 Jul 2017 | |
Cutaneous lymphoma | Phase 2 | United States | 17 Jul 2017 | |
Lymphomatoid Papulosis | Phase 2 | United States | 17 Jul 2017 | |
Mycosis Fungoides | Phase 2 | United States | 17 Jul 2017 | |
Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | United States | 17 Jul 2017 | |
Refractory Hodgkin Lymphoma | Phase 2 | Germany | 01 May 2015 |
NCT04074746 (Pubmed) Manual | Phase 1 | 42 | (zknqzxkslm) = nsfkieujhq mydzsairhw (uzvikwfika ) View more | Positive | 04 Apr 2025 | ||
Not Applicable | 7 | (dotnowpxql) = xxuxucrpdc suojzgxsnm (wwztlmpfgm ) View more | Positive | 13 Jun 2024 | |||
NCT04074746 (ASH2023) Manual | Phase 1/2 | 42 | (iykduszchn) = bhtionthpw thdozgrpda (ljbkcqmnnw ) View more | Positive | 11 Dec 2023 | ||
Phase 1/2 | 18 | (Cohort 1) | (zrdpvlsvhi) = jsiqevlwgh xjgadqygyl (sfqenktudm, hzjthhkdnu - lvbpxyrhis) View more | - | 20 Jul 2023 | ||
(Cohort 2) | (zrdpvlsvhi) = ipjtoemjqt xjgadqygyl (sfqenktudm, mljtubwdnn - tpuznkhqkj) View more | ||||||
Phase 2 | 108 | (cpfnhpahds) = tumzaebuul ecjbcrnplz (rybqydojcg ) View more | Positive | 09 Jun 2023 | |||
Phase 2 | 108 | (wouzyoxjqr) = mgdvatycjd igsqxlterr (jbqhudzmui ) View more | - | 08 Jun 2023 | |||
Phase 2 | 108 | gkmuikuero(nmnapliggp) = zdlmvmzblc wfxsdwyxsu (dgenhivsqg, axwuyjdctl - lvutcmtwuh) View more | - | 05 Jun 2023 | |||
Phase 2 | CD-30 positive Peripheral T-Cell Lymphoma CD30 Positive | 108 | (drnpqabbpo) = igmgwmmuiv jmivcoobkx (uwtpvhifum ) View more | Positive | 14 Apr 2023 | ||
(PTCL not-otherwise-specified (PTCL-NOS)) | (drnpqabbpo) = tajyeyruht jmivcoobkx (uwtpvhifum ) | ||||||
Phase 2 | 145 | (seoddmcaha) = ndhmgqdieu ulngpamqpv (vidcwzycql ) View more | Positive | 10 Dec 2022 | |||
Phase 1/2 | 30 | (folzldjvjt) = kividpewin twbowbyctd (ykroivazjz ) View more | Positive | 15 Nov 2022 |